Piramal Pharma (PPLPHARMA) Share Price Falls 2.95% to Rs 212.15 Today
- August 31, 2026
- Posted by: Harsh Piplani
- Category: News
Piramal Pharma Share Price was Rs 212.15 today, down 2.95% from the previous close, while market capitalisation stood at Rs 29,103.27 crore. Piramal Pharma is in the Large Cap category, and today’s decline is the main stock news event. The supplied data confirms the price event and shows where the stock closed in the session, but it does not establish a company-specific catalyst. For readers tracking Piramal Pharma Share Price Today, the move matters because it follows a close of Rs 218.6 and leaves the stock near the day’s low of Rs 212.15. Univest is covering the move with a price-action lens, valuation context and peer comparison so investors can place the decline in a broader market frame.
Piramal Pharma (PPLPHARMA) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 212.15 |
| Previous Close | Rs 218.6 |
| Today's Move | -Rs 6.45 (-2.95%) |
| Open | Rs 218.75 |
| High | Rs 218.75 |
| Low | Rs 212.15 |
| Turnover | Rs 1.57 crore |
| Market Capitalisation | Rs 29,103.27 crore |
| Market Cap Category | Large Cap |
Piramal Pharma Share Price Today reflected a lower session from the open itself. The stock opened at Rs 218.75, exactly at the day’s high, and then eased to a low of Rs 212.15, which was also the closing level. Against the previous close of Rs 218.6, the share price declined by Rs 6.45, or 2.95%, in a single day. Turnover was Rs 1.57 crore, which is the exact traded-value figure supplied for the session.
For a Large Cap company, the day’s price action is notable because the move came without any verified company-specific trigger in the supplied data. That means Piramal Pharma Share Price News today is driven by the recorded market outcome rather than an identified event. The gap between the day high of Rs 218.75 and the close of Rs 212.15 also shows that the stock finished at the bottom of the session’s range. In the context of Piramal Pharma Share Price Fall, investors are left with the facts of the move: lower close, lower net change and a complete retracement from the opening level. The next step in Piramal Pharma Stock News is to look at valuation and company financials for context.
Piramal Pharma (PPLPHARMA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 29,103.27 crore |
| P/B Ratio | 3.64x |
| ROE | -4.04% |
| ROCE | 1.24% |
| EPS | Rs -2.36 |
| Book Value Per Share | Rs 60.13 |
| Dividend Yield | 0% |
The profitability and earnings metrics are more restrained. ROE is -4.04, ROCE is 1.24, EPS is -2.36 and book value is Rs 60.13. Dividend yield is 0. These figures indicate that the current Piramal Pharma Share Price is not being supported by positive per-share earnings in the latest supplied data. In an article on Piramal Pharma Share Price Today, EPS and book value are important because they show that the stock is priced well above accounting book value and with negative earnings per share. Univest’s stock analysis also notes that P/B should be read alongside profitability, not in isolation. The company’s financial profile therefore adds context to the day’s share price fall without implying a cause.
For Piramal Pharma Fundamental Analysis, the key point is not prediction but comparison: the company’s valuation is richer than the industry median on P/B, while ROE and EPS are both negative and ROCE is low. That combination makes the latest Piramal Pharma Share Price News relevant for investors following company financials and market-cap context.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Benchmark Median P/E | 31.21x |
| Benchmark Average P/E | 48.1x |
| Benchmark P/E Range | 3.7x to 672.45x |
| Company P/B Ratio | 3.64x |
| Benchmark Median P/B | 2.88x |
| Benchmark Average P/B | 4.19x |
| Company ROE | -4.04% |
| Benchmark Median ROE | 11.78% |
| Benchmark Average ROE | 10.68% |
| Company ROCE | 1.24% |
| Benchmark Median ROCE | 13.6% |
| Benchmark Average ROCE | 13.27% |
| Company Market Capitalisation | Rs 29,103.27 crore |
| Benchmark Median Market Cap | Rs 670.73 crore |
| Benchmark Average Market Cap | Rs 14,040.53 crore |
Piramal Pharma operates in Healthcare and the Pharmaceuticals & Drugs industry. The supplied sector snapshot is for the same industry and covers 203 companies, which gives a useful benchmark set for Piramal Pharma Share Price analysis.The industry median P/E is 31.21, the average P/E is 48.1, and the range runs from 3.7 to 672.45.
On those measures, Piramal Pharma’s P/B of 3.64 is above the industry median P/B of 2.88 but below the industry average P/B of 4.19. Its ROE of -4.04 is below the industry median ROE of 11.78 and the industry average ROE of 10.68. Its ROCE of 1.24 is also below the industry median ROCE of 13.6 and the industry average ROCE of 13.27. Market capitalisation benchmarks in the same industry show a median of Rs 670.73 crore and an average of Rs 14,040.53 crore, while Piramal Pharma’s own market cap is Rs 29,103.27 crore, which is above both. This sector and industry context helps explain why Piramal Pharma Share Price Today is being watched closely in the healthcare pack even without any new company-specific catalyst in the supplied data.
Univest’s sector analysis indicates that the stock sits within a large industry universe, so the latest Piramal Pharma Share Price Fall should be interpreted against valuation and profitability benchmarks rather than in isolation.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,60,696.31 | 38.09 | 5.33 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,46,062.83 | 84.12 | 13.93 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,91,515.22 | 87.81 | 21.34 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,18,403.7 | 26.24 | 4.39 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,14,554.33 | 33.99 | 3.26 | 11.83 | 16 |
Piramal Pharma Share Price can also be viewed against listed healthcare peers such as Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. Among these peers, Piramal Pharma’s market cap of Rs 29,103.27 crore is smaller than Sun Pharma, Divi’s, Torrent, Zydus and Cipla, but still substantial in absolute terms.
On valuation, its P/B of 3.64 is below Sun Pharma’s 5.33, Divi’s 13.93 and Torrent’s 21.34, but above Cipla’s 3.26. Compared with Zydus at 4.39, Piramal Pharma is also lower on P/B. On profitability, Piramal Pharma’s ROE of -4.04 trails the positive ROE figures of all the listed peers in this set, and its ROCE of 1.24 is also below each of them. In Piramal Pharma Stock Analysis terms, that means the latest Piramal Pharma Share Price News sits in a weaker profitability band than the supplied peer group, even though the company’s market capitalisation is much larger than several benchmark names. Univest highlights that peer comparison is most useful when it stays anchored to exact figures, not assumptions.
Why Investors Are Watching Piramal Pharma
- Piramal Pharma Share Price fell 2.95% today to Rs 212.15 from the previous close of Rs 218.6.
- The day’s range was Rs 218.75 high and Rs 212.15 low, with the close at the session low.
- Market capitalisation stands at Rs 29,103.27 crore and the company is classified as Large Cap.
- P/B is 3.64, while ROE is -4.04, ROCE is 1.24, EPS is -2.36 and book value is Rs 60.13.
- In the healthcare industry benchmark, the company’s P/B is above the median of 2.88 and its profitability metrics are below the benchmark medians.
About Piramal Pharma
Piramal Pharma belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data identifies the company in the Large Cap category and places its market capitalisation at Rs 29,103.27 crore. That is the core company overview available for today’s Piramal Pharma Stock News update. Univest uses this factual profile to frame Piramal Pharma Share Price Today within the correct industry and market-cap setting, without adding any unsupported business description. For readers following Piramal Pharma Share Price as part of broader healthcare stock news, the company’s latest price action is best read together with its reported valuation and profitability metrics.
Track Piramal Pharma Share Price on Univest
Use Piramal Pharma (PPLPHARMA) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Investors can track Piramal Pharma Share Price on Univest for live share price updates, valuation ratios, shareholding pattern, 52-week levels and company financials. Univest also brings together Piramal Pharma Stock News, Piramal Pharma Share Price Today and broader market insights in one place for easier monitoring.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Piramal Pharma falling today?
Ans. Piramal Pharma Share Price fell 2.95% today to Rs 212.15 from Rs 218.6. The supplied data confirms the price event, but it does not establish a company-specific catalyst for the decline.
What is Piramal Pharma Share Price today?
Ans. Piramal Pharma Share Price Today is Rs 212.15. The stock closed Rs 6.45 lower than the previous close of Rs 218.6, and the day’s low was also Rs 212.15. The previous close was Rs 218.6.
What does Piramal Pharma Share Price news show for the session?
Ans. Piramal Pharma Share Price News shows a one-day decline of 2.95%, a session high of Rs 218.75, a session low of Rs 212.15 and turnover of Rs 1.57 crore. The previous close was Rs 218.6.
How large is Piramal Pharma in market-cap terms?
Ans. Piramal Pharma’s market capitalisation is Rs 29,103.27 crore, and the company is classified as Large Cap. That size context is factual and should be read alongside the day’s share price fall.
What does Piramal Pharma Fundamental Analysis show?
Ans. Piramal Pharma Fundamental Analysis shows P/B of 3.64, ROE of -4.04, ROCE of 1.24, EPS of -2.36, book value of Rs 60.13 and dividend yield of 0. These figures add context to the price action.
How does Piramal Pharma compare with healthcare peers?
Ans. Compared with peers such as Sun Pharma, Divi’s, Torrent, Zydus and Cipla, Piramal Pharma has a smaller market cap and weaker profitability metrics, while its P/B is below several peers but above Cipla.
What does the sector benchmark suggest for Piramal Pharma?
Ans. In the same-industry benchmark of 203 companies, Piramal Pharma’s P/B is above the median, while ROE and ROCE are below the median and average. That gives the stock a mixed sector comparison.
Is Piramal Pharma Share Price tied to positive earnings right now?
Ans. The supplied data shows EPS of -2.36, so the current Piramal Pharma Share Price is not supported by positive per-share earnings in this dataset. Book value is Rs 60.13 and dividend yield is 0.
